A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
Open Access
- 31 October 2010
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 5 (10), 1655-1661
- https://doi.org/10.1097/jto.0b013e3181ec18db
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasionMolecular Cancer Therapeutics, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Molecular pathways in malignant pleural mesotheliomaCancer Letters, 2006
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- O-26 Thalidomide alone or in combination with cisplatin/Gemcitabine in malignant pleural mesothelioma (MM); Interim results from two parallel non randomized phase II studiesLung Cancer, 2003
- Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group BLung Cancer, 2001
- VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cellsOncogene, 1999